You are here: Industry Insights > Rheumatoid Arthritis

News List

Which of the Blockbuster Drugs on the Autoimmune Drug Market Will Show the Glory that Humira Had?(4) Siyi
June 11, 2018
TNFα inhibitors have been occupying most of the rheumatoid arthritis (RA) drug market owing to their quick acting clinically...
FDA greenlights Lilly's Olumiant in rheumatoid arthritis, with major caveats pharmafile
June 07, 2018
Eli Lilly has announced that its oral JAK inhibitor Olumiant (baricitinib) has received FDA approval for the treatment of moderately-to-severely active rheumatoid arthritis (RA) in adult patients who have had an inadequate response to one or more tumour n
Global Rheumatoid Arthritis Drugs Markets 2018-2022 - Increasing Use of Technology / 3D Printing Tec biospace
March 22, 2018
The "Drugs for Rheumatoid Arthritis: Global Markets to 2022" report has been added to Research And Markets' offering.
Autoimmune disease research community gets boost from AMP RA/SLE study results europeanpharmaceuticalreview
February 26, 2018
Data from the Phase I study of collaborative industry partnership AMP are now available, meaning scientists can benefit from access to important research about Rheumatoid Arthritis and Systemic Lupus Erythematosus.
Maintaining sufficient vitamin D levels may help to prevent rheumatoid arthritis worldpharmanews
November 22, 2017
Maintaining sufficient vitamin D levels may help to prevent the onset of inflammatory diseases like rheumatoid arthritis, research led by the University of Birmingham has discovered.
Adalimumab biosimilar exhibits same efficacy and safety for rheumatoid arthritis as originator pharmaceutical-journal
November 13, 2017
The trial data was presented at the American College of Rheumatology / Association of Rheumatology Health Professionals Annual Meeting in San Diego, California by the manufacturers of Cyltezo.
Scientists find a new way to acquire viable cells from cryopreserved tissue samples biospectrumasia
November 07, 2017
The researchers aim to discover new, more effective ways to treat the inflammatory response that causes these chronic diseases by identifying the cell types and signals central to driving inflammation in patients with rheumatoid arthritis
Korean scientists invent hydrogel to combat rheumatoid arthritis biospectrumasia
October 13, 2017
The research team developed a gel using acrylamide as a base material and a new crosslinker to keep it in place.
Lilly, Incyte reveal earlier-than-expected refiling for baricitinib fiercebiotech
August 31, 2017
New application will include new safety and efficacy data.
Lilly to File Baricitinib Resubmission to U.S. FDA before end of January 2018 americanpharmaceuticalreview
August 31, 2017
Eli Lilly and Incyte announced that Lilly will resubmit the New Drug Application (NDA) for baricitinib before the end of January 2018. Baricitinib is a once-daily oral investigational medication for the treatment of patients with moderate-to-severe rheuma

Previous page 1 2 3 4 5 6 Next page